Evidence map›Paper›PMID 28864936›Full record

ArticleMycopathologia2018

A Case of Cutaneous Mycosis Caused by Scedosporium dehoogii on an Immunocompromised Patient.

Yuichi Sakata, Fumiaki Taga, Tsuyoshi Ushigami, Kiminobu Takeda, Kazushi Anzawa, Akiko Nishibu, Takashi Mochizuki

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Mycopathologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. RecurrentJournal of fungi (Basel, Switzerland) · 2023
    Review
  6. A case of cutaneousSkin health and disease · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yuichi SakataDepartment of Dermatology, Kanazawa Medical University, Daigaku 1-1, Uchinada, Ishikawa, 920-0293, Japan.
Fumiaki TagaDepartment of Dermatology, Kanazawa Medical University, Daigaku 1-1, Uchinada, Ishikawa, 920-0293, Japan.
Tsuyoshi UshigamiDepartment of Dermatology, Kanazawa Medical University, Daigaku 1-1, Uchinada, Ishikawa, 920-0293, Japan.
Kiminobu TakedaDepartment of Dermatology, Kanazawa Medical University, Daigaku 1-1, Uchinada, Ishikawa, 920-0293, Japan.
Kazushi AnzawaDepartment of Dermatology, Kanazawa Medical University, Daigaku 1-1, Uchinada, Ishikawa, 920-0293, Japan.
Akiko NishibuDepartment of Dermatology, Kanazawa Medical University, Daigaku 1-1, Uchinada, Ishikawa, 920-0293, Japan.
Takashi MochizukiDepartment of Dermatology, Kanazawa Medical University, Daigaku 1-1, Uchinada, Ishikawa, 920-0293, Japan. mocizuki@kanazawa-med.ac.jp.ORCID http://orcid.org/0000-0002-3793-980X
Kanazawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report describes a 77-year-old man with cutaneous mycosis caused by Scedosporium dehoogii while taking oral betamethasone and tacrolimus for the treatment of rheumatoid arthritis. At examination in our clinic, the patient had multiple cystic lesions and nodules with slight tenderness, varying in size up to 4 cm, on his left knee and shin. He had not noticed any traumatic injury at the site of the lesions. Fungal cultures of samples taken from the abscesses, scales, and crusts of the lesions yielded white, later grayish brown, fluffy surfaced colonies. Partial sequencing of the β-tubulin gene confirmed the species of the isolate. The patient was initially treated with oral voriconazole and local hyperthermia, but experienced hepatic injury 2 weeks later. His treatment was changed to itraconazole (ITC) and local hyperthermia, followed by a combination of ITC and terbinafine. The patient recovered completely during the 12-month course of treatment.

Indexed as

Immunocompromised HostAgedAntifungal AgentsArthritis, RheumatoidDermatomycosesHumansImmunosuppressive AgentsMaleMicrobiological TechniquesScedosporiumSequence Analysis, DNATreatment OutcomeTubulinAntifungal AgentsImmunosuppressive AgentsTubulinCutaneous infectionImmunocompromised patientItraconazoleScedosporium dehoogiiTerbinafineVoriconazole

Identifiers

PMID28864936
OpenAlexW2750630652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.